Detailed simultaneous testing of polymorphisms and CNV in all three of these genes (FcγRIIA, FcγRIIC, and FcγRIIIA) has yet to be evaluated for associations with clinical outcome in clinical trials of ADCC-inducing tumor-reactive mAbs. The gene discussed is FCGR3A; the disease is neoplasm.